Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009

Journal of Clinical Pharmacology

Volumn 49, Issue 3, 2009, Pages 312-322

  Geller, J Christoph ^a,f   Egstrup, Kenneth ^b   Kulakowski, Piotr ^c   Rosenqvist, Mårten ^b   Jansson, Maria Aunes ^d   Berggren, Anders ^d   Edvardsson, Nils ^d   Sager, Philip ^d   Crijns, Harry J ^e  

^a Zentralklinik   (Germany)

^b Grochowski Hospital ^*

^c GROCHOWSKI HOSPITAL   (Poland)

^d ASTRAZENECA   (United Kingdom)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

Atrial fibrillation; AZD7009; DC cardioversion; Pharmacological cardioversion

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SICK SINUS SYNDROME; SIDE EFFECT; SINUS RHYTHM; TORSADE DES POINTES;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANIC CHEMICALS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61449104512     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008329549     Document Type: Article

References (17)

1. Edvardsson N., Walfridsson H., Aass H., Rossvoll O. Predominant effects on atrial versus ventricular refractoriness in man by the novel antiarrhythmic agent AZD7009. Eur Heart J. 2005 ; 26 (suppl 1). 506.
2. Goldstein RN, Khrestian C., Carlsson L., Waldo AL AZD7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol. 2004 ; 15: 1444-1450.
3. Persson F., Carlsson L., Duker G., Jacobson I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J Cardiovasc Electrophysiol. 2005 ; 16: 329-341.
4. Roden DM, Anderson ME Proarrhythmia. Handb Exp Pharmacol. 2006 ;(171). 73-97.
5. Antzelevitch C. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm. 2005 ; 2: S9 - S15.
6. Wu Y., Carlsson L., Liu T., Kowey PR, Yan GX Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol. 2005 ; 16: 898-904.
7. Crijns HJ, Van Gelder IC, Walfridsson H., et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm. 2006 ; 3: 1321-1331.
8. Dota C., Skallefell B., Edvardsson N., Fager G. Computer-based analysis of dynamic QT changes: toward high precision and individual rate correction. Ann Noninvasive Electrocardiol. 2002 ; 7: 289-301.
9. Blaauw Y., Schotten U., van HA, Neuberger HR, Allessie MA Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. Cardiovasc Res. 2007 ; 75: 89-98.
10. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol. 1996 ; 28: 130-136.
11. Bianconi L., Castro A., Dinelli M., et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000 ; 21: 1265-1273.
12. Singh S., Zoble RG, Yellen L., et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000 ; 102: 2385-2390.
13. Hongo RH, Themistoclakis S., Raviele A., et al. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol. 2004 ; 44: 864-868.
14. Chiladakis JA, Kalogeropoulos A., Patsouras N., Manolis AS Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. J Am Coll Cardiol. 2004 ; 44: 859-863.
15. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005 ; 352: 1861-1872.
16. Roy D., Pratt CM, Torp-Pedersen C., et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008 ; 117: 1518-1525.
17. Wyse KR, Ye V., Campbell TJ Action potential prolongation exhibits simple dose-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide: implications for proarrhythmia due to triggered activity. J Cardiovasc Pharmacol. 1993 ; 21: 316-322.